Optimum dosing regimen for repeated low dose allergen challenge in chronic allergic asthma

S. K. Babu, J. Lordan, A. Corkhill, S. Wilson, S. T. Holgate, H. S. Arshad (Southampton, United Kingdom)

Source: Annual Congress 2001 - Airway provocation: what's new?
Session: Airway provocation: what's new?
Session type: Thematic Poster Session
Number: 724
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. K. Babu, J. Lordan, A. Corkhill, S. Wilson, S. T. Holgate, H. S. Arshad (Southampton, United Kingdom). Optimum dosing regimen for repeated low dose allergen challenge in chronic allergic asthma. Eur Respir J 2001; 16: Suppl. 31, 724

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Decreasing dose protocol for omalizumab treatment in oral corticosteroid allergic asthma patients
Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E
Year: 2011


The effects of two weeks of repeated low-dose allergen exposure on sputum eosinophilic and neutrophilic inflammation in atopic asthma: protection by inhaled steroids?
Source: Eur Respir J 2001; 18: Suppl. 33, 482s
Year: 2001

Bronchial cell infiltrate after two weeks, repeated low-dose allergen exposure in atopic asthma: protection by inhaled steroids?
Source: Eur Respir J 2002; 20: Suppl. 38, 588s
Year: 2002

The effect of single dose montelukast and desloratadine, alone and in combination, on the allergen induced late airway response in atopic asthma
Source: Annual Congress 2008 - New mechanisms in the pathogenesis of asthma and its response to treatment
Year: 2008



Efficacy of short-term high dose predonisolone therapy in acute exacerbation of bronchial asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 71s
Year: 2001

Reduced late asthmatic response by repeated low-dose allergen exposure
Source: Eur Respir J 2001; 17: 872-880
Year: 2001



Influence of formoterol alone and its fixed combination with budesonide on airway responsiveness and airway inflammation induced by repeated low dose allergen challenge
Source: Eur Respir J 2007; 30: Suppl. 51, 749s
Year: 2007

Tolerance to the protective effect of salmeterol on allergen challenge in mild untreated asthmatics and in moderate asthmatics on inhaled corticosteroid treatment
Source: Eur Respir J 2001; 18: Suppl. 33, 103s
Year: 2001

Omalizumab therapy reduces oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma: European real-life experience
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009


Repeated inhaled airway allergen challenge model in asthma
Source: Annual Congress 2009 - Inflammation and airways
Year: 2009

Effect of IgE sensitization and allergen exposure on exhaled NO during inhaled corticosteroid (ICS) treatment in patients with asthma
Source: Annual Congress 2007 - Primary care respiratory problems
Year: 2007


High or standard initial dose of budesonide to control mild-to-moderate asthma?
Source: Eur Respir J 2001; 17: 856-862
Year: 2001



Budesonide/formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroids in patients with mild persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 387s
Year: 2002

Effect of antileukotriene therapy on methacholine challenge test in patients with mild asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 587s
Year: 2004

Utility of high dose inhaled fluticasone therapy for the early management of acute exacerbations of asthma
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009


Relationships of mannitol challenge to methacholine challenge and inflammatory markers in asthmatics receiving inhaled corticosteroids
Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease
Year: 2012



Systemic steroid use in children with allergic (IgE-mediated) asthma receiving omalizumab
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010

Hypoallergenic high dose scit as add-on therapy in children with allergic asthma caused by house dust mites
Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases
Year: 2009


Persistency of treatment response to omalizumab in patients with severe allergic (IgE-mediated) asthma
Source: Annual Congress 2009 - Severe asthma and its treatment
Year: 2009


Does treatment of allergic rhinitis with intranasal steroids improve asthma control
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases
Year: 2008